Sentences with phrase «drug prices paid»

Not exact matches

When you have these kinds of price hikes, which in some cases I believe are just simply criminal and they are done because of greed, it's like putting a gun to somebody's head and saying you need to pay me this very high price for the drug or you die.

In order for companies like UniQure to make money on these novel drugs, they'll have to be priced at an exorbitant premium, which few if any patients could ever pay.

Besides, if Mylan were to actually reduce the price of EpiPen, it would have ramifications other than just lowering what individuals pay for the drug.

Often it turns out that the price increases by Valeant and Turing that have provoked the most criticism have been on drugs that are off - patent — meaning generic competitors are free to enter the market, typically bringing the price that most people pay for the drugs way down.

There's a chain of events separating a drug's topline list price, what benefits managers and insurers pay, and what customers ultimately wind up paying.

Don't get drunk, abuse drugs, or abuse the situation you're in because the truth will come out and your career and work relationships will pay the price.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In fact, when pressed on the issue, Verheul speculated that perhaps costs would not increase since Canadians already pays higher prices for pharmaceutical drugs than consumers in European countries such as the UK, France or Germany.

Provincial governments, strapped for cash and facing ballooning deficits, have been hacking away at the prices they pay for generic drugs.

The VA often pays the lowest prices for drugs in the nation, being able to negotiate what it pays for medications, often at a steep discount compared to other government agencies and Medicare.

If Issue 2, or the Drug Price Relief Act, passes, the act would require the state and state agencies, including Ohio Medicaid, to pay the same or lower prices for prescription drugs as the U.S. Department of Veterans Affairs does.

Issue 2, or the Drug Price Relief Act, would require Ohio to pay no more for prescription drugs than the U.S. Department of Veterans Affairs.

As a result, the drug manufacturers end up setting two prices for their drugs — the higher list price and the lower, secret, «real» price that insurers pay.

Insurers do not pay the list prices that the drug makers set.

That's because plans increasingly carry high deductibles, which require patients to pay for their drug costs themselves until they hit a certain limit, as well as to pay a percentage of the list price even after their deductible is met.

A lawsuit filed Monday accused three makers of insulin of conspiring to drive up the prices of their lifesaving drugs, harming patients who were being asked to pay for a growing share of their drug bills.

It could, say, lower the prices paid to monopoly hospitals, eliminate services that have no value or tighten the supply chain for drugs.

The lawsuit, comprised of many federal cases consolidated in United States District Court for the District of Massachusetts in Boston, charged that TAP Pharmaceutical Products, Inc., Abbott Laboratories (NYSE: ABT) and Takeda Pharmaceutical Company Limited (NYSE: TDCHF) conspired to fraudulently market, sell and distribute Lupron, causing consumers to pay inflated prices for the drug.

Investors challenge pay packages at pharma companies, saying they incentivize drug price hikes.

We are now paying the price of that blind and irresponsible folly — in a drug war that we are not winning, in burgeoning crime that has made city neighborhoods uninhabitable, in teenage pregnancies and «children having children,» in rampant abortions, swelling welfare roles, sexually transmitted diseases, self - indulgent neglect of community good, and countless ruined lives.

Whether the lonely person responds by losing his identity in the anonymous herd, clinging frighteningly to others, or deadens the inner ache with drugs, overeating or compulsive work, the price he pays is the increasing loneliness of superficial relationships.

Coffee farmers who receive a higher price for their quality coffee are also less likely to exploit their land for other purposes — whether it is turning to less environmentally - friendly but higher paying crops (including drugs), logging, or pasture.

If they use drugs and alcohol to avoid learning these tasks, they will pay a price in adulthood.

If Americans paid world prices for drugs, the profits would not be able to justify spending billions of dollars on getting FDA approval for that drug to be sold.

Price segregation allows vital drugs to be provided at cost (or closer to it) for low - income nations, while American customers pay high enough prices to fund research and development of new medications.

The country is currently paying twice the price: of militarised anti-narcotics strategies and increasing medical problems related to drug use.

Medicare too creates a schedule of coverages and drug prices that it will pay for, but that negotiation is done with private insurance companies, not directly with providers.

Medicaid produces a schedule of drugs that it will pay for, and the maximum price it will pay for them (which it reviews every year).

While about 33 % of beneficiaries are part of this system where insurance can negotiate, known as «Medicare Advantage», most Medicare beneficiaries receive benefits directly from the government agency involved which pays 106 % of the «standard price» for prescription drugs without negotiation.

(Posted 24 December 2011) Significant current scandals, and those yet to come In no particular order Top salaries and bonuses - boardroom and shareholder individual responsibility The multiple between top and average pay Lawyers fees - the cost of the legal process Medical negligence claims against the NHS Care and treatment in the NHS «No win, no fee» personal injury compensation Democracy and the voting system Lords reform Political party funding The domestic energy market and pricing The Tax system and its inefficiencies and complexities Subsidies for new energy generation schemes The amount of crime fuelled by Drugs The availability of drugs in prDrugs The availability of drugs in prdrugs in prison.

Gag clauses prohibit pharmacists from telling consumers information regarding the price of medication, the availability of alternative medications, or that the drug may actually cost less if they pay out of pocket.

The Lib Dem leader is keen to use his drug policy to win back votes from young people he may have lost over tuition fees, but there's a price to be paid for that and the Daily Mail and right - wing think tanks are intent on making sure he pays it.

A number of new, highly effective therapies to treat both Hepatitis C and HIV / AIDS have been approved by the Food and Drug Administration in recent years, but their extraordinary costs have raised questions about states» ability to pay the sticker price.

The public should demand that Big Pharma immediately disgorge some of their profits, stop charging Americans the highest prices in the world, and create a fund to pay for research on drugs that can curb the spread of infectious diseases.

«That is a small price to pay for the benefits of the drugs,» says Ducharme.

Michael Price, 13 April Drug development companies are now hiring more computational biologists, creating an abundance of high - paying jobs.

Implementation of reference pricing was associated with a 7 percent increase in prescriptions filled for the low - price reference drug within its therapeutic class, a 14 percent decrease in average price paid, and a 5 percent increase in consumer cost sharing, the study found.

Under the reference pricing strategy, the insurer or employer establishes its maximum contribution towards the price of therapeutically similar drugs and then the patient must pay the remainder out of pocket.

«With reference pricing, the employer or insurer will make a contribution towards paying for the prescription drug chosen by the patient, and the patient will pay the remainder,» said lead author James C. Robinson, director of the Berkeley Center for Health Technology at the School of Public Health.

If we choose to regulate the industry, we have to be willing to pay the price for that, which means there won't be cheap antimalarial drugs developed and there won't be potential biofuels developed and other drugs for other diseases and cleaning up the environment and all the things that come from this area.

The rise of the low - price chemist — able to buy products in bulk at a cheaper price — has taken the sting out of paying for both prescription and over-the-counter drugs.

The drug tamoxifen, for instance, helps many women with breast cancer, but they pay the price of an increased risk of endometrial cancer.1 Medicine would do much better concentrating on genuine prevention — especially through nutrition.

I love great makeup, but HATE paying crazy prices, so seeing which drug store brands worked best was AWESOME.

Doug Kenney was just a funny guy who found success at an early age, started making some big mistakes (like lying, cheating, and hardcore drug abuse), and paid the ultimate price at the age of 33.

On the other hand, if you test positive for medical conditions and / or drug usage, you may have to pay a higher price for your policy.

Generic drugs are very cheap in Thailand but unless you already have an idea of how much you should be paying, you will be charged double or triple the real price.

More controversially, he paid six unemployed Cubans to have a line tatooed across their backs for 30 dollars and he later did the same to a group of drug - addicted prostitutes, paying them the price of a shot of heroin in return.

In the settlement, GlaxoSmithKline agreed to plead guilty and to pay a $ 3 billion fine to resolve its criminal and civil liability arising from the company's unlawful promotion of certain prescription drugs, its failure to report certain safety data, and its civil liability for alleged false price reporting practices.

If you do not get prior authorization, you'll pay full price for the drug.

They may require that, if you choose a brand - name drug (when an equivalent generic is available), you to pay the price difference between the two.